MEN1 and leukemia: They reported that combination of EPZ004777 and MI-2-2 (an inhibitor of MLL–Menin interaction) enhanced the down-regulation of important leukemia genes (i.e., MYC, HOXA9, and MEIS1) and anti-proliferative effects against MLL-r leukemia cells, compared to either single-agent treatment (Dafflon et al., 2017).